ABI
BCR

Adamant Biomedical Investments’s CR Bard Inc. BCR Stock Holding History

Adamant Biomedical Investments’s Portfolio BCR Stock Details BCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		$1.67M Hold
10,000
– – 0.4% 72
2014
Q3 		$1.43M Buy
+10,000
New +$1.48M 0.36% 72

Other funds holding BCR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
YAM
Yacktman Asset Management Austin, Texas $7.5B AUM 22.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Adamant Biomedical Investments's BCR Position: Q4 2014 in Review

Adamant Biomedical Investments held its CR Bard Inc. (BCR) position steady in Q4 2014 at 10,000 shares worth $1.67M. The position accounts for 0.4% of the portfolio, ranked #72.

Adamant Biomedical Investments first reported a position in BCR in Q3 2014 and has held it in 2 quarters since. 577 funds tracked by Wall St. Rank hold BCR as of Q4 2014.

  • Adamant Biomedical Investments held 10,000 shares of CR Bard Inc. worth $1.67M as of Q4 2014.
  • Adamant Biomedical Investments left its CR Bard Inc. share count unchanged in Q4 2014.
  • CR Bard Inc. made up 0.4% of Adamant Biomedical Investments's portfolio in Q4 2014, its #72 holding.
  • Adamant Biomedical Investments first reported a position in CR Bard Inc. in Q3 2014 and has held it in 2 quarters since.
  • 577 funds tracked by Wall St. Rank held CR Bard Inc. as of Q4 2014.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.